We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

BiomX Inc (PHGE) USD0.0001

Sell:$0.54 Buy:$0.84 Change: No change
Market closed |  Prices as at close on 21 June 2022 | Switch to live prices |
Sell:$0.54
Buy:$0.84
Change: No change
Market closed |  Prices as at close on 21 June 2022 | Switch to live prices |
Sell:$0.54
Buy:$0.84
Change: No change
Market closed |  Prices as at close on 21 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Contact details

Address:
22 Einstein St., Floor 5
NESS-ZIONA
7414001
Israel
Telephone:
+1 (646) 4659000
Website:
https://www.biomx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PHGE
ISIN:
US09090D1037
Market cap:
$19.81 million
Shares in issue:
29.78 million
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Jonathan Solomon
    Chief Executive Officer, Director
  • Marina Wolfson
    Chief Financial Officer
  • Merav Bassan
    Chief Development Officer
  • Assaf Oron
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.